S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NASDAQ:TGTX

TG Therapeutics (TGTX) Stock Forecast, Price & News

$9.30
-0.29 (-3.02%)
(As of 09/20/2023 ET)
Compare
Today's Range
$9.29
$9.66
50-Day Range
$9.30
$22.10
52-Week Range
$4.86
$35.67
Volume
2.64 million shs
Average Volume
3.71 million shs
Market Capitalization
$1.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.14

TG Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
148.8% Upside
$23.14 Price Target
Short Interest
Bearish
20.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
0.46mentions of TG Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$1.01 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.77) to $0.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

565th out of 961 stocks

Pharmaceutical Preparations Industry

262nd out of 455 stocks


TGTX stock logo

About TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics Inc is a biopharmaceutical company that develops and commercializes innovative treatments for multiple sclerosis (MS) and other autoimmune diseases. The company, founded in 2012, is headquartered in New York City and has operations in the United States and Europe. The company aims to provide new and effective therapies to patients with unmet medical needs.

TG Therapeutics has made significant achievements since its inception but has also experienced significant setbacks. The company initially rose to fame by producing the cancer drug Ukoniq which was later pulled from the market due to its ineffectiveness. The company shifted focus and received FDA approvals for a multiple sclerosis drug, Briumvi, for relapsing forms of multiple sclerosis. Additionally, the company conducts extensive clinical trials for other product candidates. These product candidates can potentially provide new treatment options for patients with B-cell malignancies and autoimmune diseases.

TG Therapeutics has a talented and experienced management team dedicated to advancing the company's mission. The current CEO and co-founder of the company is Michael S. Weiss, who has over 25 years of experience in the biopharmaceutical industry. TG Therapeutics has seen financial growth and decline over the past few years. The company has reported significant losses primarily due to removing Ukoniq from its product line and increased investment in clinical development and research activities. 

TG Therapeutics has seen significant volatility in its stock price over the past few years. In 2021, the stock price increased by over 200% due to positive clinical trial results for its product candidates. However, in 2022, the stock price experienced a sharp decline due to concerns about removing the approved drug Ukoniq from the market, delays in clinical development and increased competition. 

TG Therapeutics operates in the biopharmaceutical industry, characterized by high innovation levels and significant regulatory oversight. The industry is also subject to political and economic pressures, including changes in healthcare policy and pricing pressures from payers.

TG Therapeutics faces competition from other companies developing cancer and autoimmune disease treatments, including large pharmaceutical companies such as Roche and Novartis. However, the company's focus on developing novel therapies for unmet medical needs gives it a competitive advantage.

TG Therapeutics has several growth opportunities in its pipeline. The company is currently developing new product candidates which have the potential to provide new treatment options for patients with MS, B-cell malignancies and autoimmune diseases. Additionally, the company may pursue strategic acquisitions or partnerships to expand its product portfolio and reach new markets.

TG Therapeutics faces risks and challenges that may impact its future growth and success. These include changes in healthcare policy and pricing pressures from payers and increased competition from other companies in the market. Additionally, the company is subject to regulatory oversight and must successfully navigate the clinical development and approval process for its product candidates. Failure to do so may result in delays, increased costs, and potential setbacks for the company.

The company's financial performance is also subject to risks, such as changes in interest rates and the availability of financing. The company's debt levels may limit its ability to invest in research and development. Any significant changes in ownership or management may also disrupt operations and impact the company's growth potential.

Furthermore, the success of TG Therapeutics' product candidates is not guaranteed, and the company may need help demonstrating their safety and efficacy in clinical trials. Failure to obtain regulatory approval for these products or to effectively commercialize them may significantly impact the company's financial performance and market position.

TGTX Price History

TGTX Stock News Headlines

TG Therapeutics (NASDAQ:TGTX) Receives Buy Rating from HC Wainwright
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
3 Very Oversold Biotech Stocks to Buy Right Now
10 Oversold Healthcare Stocks to Buy
TGTX Aug 2023 25.000 put
TGTX Aug 2023 28.000 call
TG Therapeutics (TGTX) Gets a Buy from B.Riley Financial
See More Headlines
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Company Calendar

Last Earnings
8/01/2023
Today
9/21/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TGTX
Employees
244
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.14
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+148.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-198,340,000.00
Net Margins
-730.34%
Pretax Margin
-730.34%

Debt

Sales & Book Value

Annual Sales
$2.79 million
Book Value
$0.40 per share

Miscellaneous

Free Float
137,088,000
Market Cap
$1.40 billion
Optionable
Optionable
Beta
2.09
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael S. Weiss Esq.Mr. Michael S. Weiss Esq. (Age 57)
    Chairman, CEO & Pres
    Comp: $1.97M
  • Mr. Sean A. Power CPAMr. Sean A. Power CPA (Age 41)
    CPA, CFO, Corp. Sec. & Treasurer
    Comp: $652.6k
  • Jenna Bosco
    Sr. VP of Corp. Communications
  • Mr. Adam Waldman
    Chief Commercialization Officer













TGTX Stock - Frequently Asked Questions

Should I buy or sell TG Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TGTX shares.
View TGTX analyst ratings
or view top-rated stocks.

What is TG Therapeutics' stock price forecast for 2023?

7 analysts have issued twelve-month price targets for TG Therapeutics' shares. Their TGTX share price forecasts range from $6.00 to $41.00. On average, they expect the company's stock price to reach $23.14 in the next year. This suggests a possible upside of 148.8% from the stock's current price.
View analysts price targets for TGTX
or view top-rated stocks among Wall Street analysts.

How have TGTX shares performed in 2023?

TG Therapeutics' stock was trading at $11.83 at the start of the year. Since then, TGTX stock has decreased by 21.4% and is now trading at $9.30.
View the best growth stocks for 2023 here
.

When is TG Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our TGTX earnings forecast
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its earnings results on Tuesday, August, 1st. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.08. The biopharmaceutical company had revenue of $16.07 million for the quarter, compared to the consensus estimate of $17.39 million. TG Therapeutics had a negative trailing twelve-month return on equity of 309.58% and a negative net margin of 730.34%. The business's revenue for the quarter was up 2606.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) earnings per share.

What ETFs hold TG Therapeutics' stock?

ETFs with the largest weight of TG Therapeutics (NASDAQ:TGTX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE).AdvisorShares Let Bob AI Powered Momentum ETF (LETB).

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.57%), State Street Corp (3.73%), Geode Capital Management LLC (1.87%), Holocene Advisors LP (1.08%), Goldman Sachs Group Inc. (0.94%) and Northern Trust Corp (0.89%). Insiders that own company stock include Laurence N Charney, Michael S Weiss, Sagar Lonial, Sean A Power and Yann Echelard.
View institutional ownership trends
.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $9.30.

How much money does TG Therapeutics make?

TG Therapeutics (NASDAQ:TGTX) has a market capitalization of $1.40 billion and generates $2.79 million in revenue each year. The biopharmaceutical company earns $-198,340,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does TG Therapeutics have?

The company employs 244 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.tgtherapeutics.com. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at ir@tgtxinc.com, or via fax at 212-554-4531.

This page (NASDAQ:TGTX) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -